Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Maintains Overweight on Medtronic, Raises Price Target to $105

Author: Benzinga Newsdesk | August 22, 2024 10:24am
Barclays analyst Matt Miksic maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $104 to $105.

Posted In: MDT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist